Jorge Bartolome is the founder of Areteia Therapeutics. Areteia Therapeutics has raised $350M in total funding. Latest round: Series A.
Jorge Bartolome is the CEO at Areteia Therapeutics, a private clinical-stage biotech company focused on developing therapies for asthma. The company raised $350 million in a Series A round led by Bain Capital to advance its lead candidate, dexpramipexole, a small molecule in phase 3 development for asthma. Bartolome previously served as President of Canada for Janssen and as SVP of the US Respiratory Business Unit of GSK.
Full founder directory · Investor directory · Company funding database · Fundraising library